An American study confirmed that in NSCLC, B2M gene mutation could cause the deletion of MHC I molecule on the cancer cell surface, further lead to the recognition obstacle of CD8+ T cells, and induce immune resistance (88). The gene discussed is CD8A; the disease is cancer.